IL-1F6 / IL-36 Alpha / IL36A Drug Discovery Landscape & Assay Solutions
- By admin
- 10 Sep 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Autoimmune Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-36 Alpha drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-36 Alpha Recombinant Active Protein (N-term truncated active form, high purity >95%, Endotoxin <0.1 EU/μg). Sequence Verified (HEK293 or E. coli expressed). | View IL36A Products |
| Gene Delivery | IL-36 Alpha Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and overexpression assays. | View IL36A Products |
| Benchmark Ab | Anti-IL-36R Recombinant Biosimilar (Sequence of Spesolimab / Imsidolimab). Recombinant positive control for receptor-blocking verification. | View IL36R Products |
| Validator | IL-36 Alpha siRNA Set. For target knockdown verification in primary keratinocytes or epithelial cells. | View IL36A Products |
| Related Target A | IL-36 Receptor (IL-36R / IL-1Rrp2 / IL1RL2). Signaling receptor for IL-36 ligands; crucial for neutralizing antibody screening. | View IL36R Products |
| Related Target B | IL-1RAcP (IL-1RAP). Co-receptor recruited by the IL-36/IL-36R complex to initiate downstream NF-κB signaling. | View IL1RAP Products |
| Related Target C | IL-36Ra (IL36RN). Natural antagonist for competitive binding assays and mechanism studies. | View IL36RN Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| N-terminal Processing Dependency | Truncated active form (removing first 5-6 amino acids) designed for maximum receptor affinity and signaling potency. |
| Cross-species Evaluation | Human/Mouse/Cynomolgus monkey ortholog proteins available with >95% purity for preclinical in vivo modeling. |
| Subfamily Counter Screening | Homolog panel proteins (IL-36 Beta, IL-36 Gamma) strictly verified by sequence and molecular weight. |
| Lack of Controls | Clinical Benchmark Antibodies (Spesolimab and Imsidolimab biosimilars) included for assay validation. |
| False Positives | Sequence-verified siRNA sets and validated negative controls included for specificity checks. |
Live IL-36 Alpha R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-36 pathway therapeutics is intensifying. Major players are shifting focus from traditional systemic anti-IL-36R monoclonal antibodies to localized delivery, tissue-specific targeting, and oral small-molecule inhibitors of downstream components. As first-generation therapies like Spesolimab reach the clinic for Generalized Pustular Psoriasis (GPP), the next wave of R&D is targeting broader indications including Inflammatory Bowel Disease (IBD), Netherton Syndrome, and COPD. Specifically, direct targeting of IL-36 Alpha aims to address localized inflammatory skin and bowel diseases while preserving baseline mucosal immunity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Anti-IL-36R) | Boehringer Ingelheim, AnaptysBio | GPP, Ulcerative Colitis | Receptor-blocking assays (Need active IL-36 Alpha ligand to stimulate IL-36R cells) |
| Monoclonal Antibody (Anti-IL-36 Ligands) | Academic & Early Biotech | Atopic Dermatitis, Psoriasis | Ligand neutralization assays (Need high-purity, low-endotoxin monomeric IL-36 Alpha) |
| Bispecific Antibody | Various Biotechs | Inflammatory Bowel Disease | Dual-binding validation (Need cross-reactive Abs and multi-target panels) |
| Small Molecule / Protease Inhibitors | Incyte, Novartis | Neutrophilic Dermatoses | Enzymatic activation screening (Need precursor vs. cleaved/active IL-36 Alpha proteins) |
Key Genetic Variants in IL36A
Reported genetic variants in IL36A include rs895497, rs28938798, and rs28947175 (UniProt Q9UHA7). These polymorphisms may influence protein function or disease susceptibility and should be considered in target validation and patient stratification strategies.
Related Targets Summary
- IL-36R (IL1RL2): Primary receptor for IL-36 signaling; central for receptor-blocking assays.
- IL-1RAcP (IL-1RAP): Essential co-receptor recruited upon ligand binding; target for broad IL-1/IL-36 pathway bispecific antibodies.
- IL-36Ra (IL36RN): Natural antagonist; important for competitive binding studies and understanding disease mechanisms.
- IL-23A: Synergistic with IL-36 pathway in psoriasis; combination targeting (e.g., IL-36R + IL-23) is an emerging design strategy.
Note: All reagents are offered to support preclinical drug discovery. For custom assay development or large-scale requests, please contact TarMart.